Literature DB >> 12577314

SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling.

Aleksandar Francki1, Kouros Motamed, Timothy D McClure, Marcus Kaya, Carrie Murri, David J Blake, Juliet G Carbon, E Helene Sage.   

Abstract

Glomerular mesangial cells both synthesize and respond to insulin-like growth factor-1 (IGF-1). Increased activity of the IGF signaling pathway has been implicated as a major contributor to renal enlargement and subsequent development of diabetic nephropathy. Secreted protein acidic and rich in cysteine (SPARC), a matricellular protein, has been shown to modulate the interaction of cells with growth factors and extracellular matrix. We have reported that primary glomerular mesangial cells derived from SPARC-null mice exhibit an accelerated rate of proliferation and produce substantially decreased levels of transforming growth factor beta1 (TGF-beta1) in comparison to their wild-type counterparts (Francki et al. [1999] J. Biol. Chem. 274: 32145-32152). Herein we present evidence that SPARC modulates IGF-dependent signaling in glomerular mesangial cells. SPARC-null mesangial cells produce increased amounts of IGF-1 and -2, as well as IGF-1 receptor (IGF-1R) in comparison to wild-type cells. Addition of recombinant SPARC to SPARC-null cells inhibited IGF-1-stimulated mitogen activated protein kinase (MAPK) activation and DNA synthesis. We also show that the observed accelerated rate of basal and IGF-1-stimulated proliferation in mesangial cells derived from SPARC-null animals is due, at least in part, to markedly diminished levels of cyclin D1 and the cyclin-dependent kinase (cdk) inhibitors p21 and p27. Since expression of SPARC in the glomerulus is especially prominent during renal injury, our findings substantiate previous claims that SPARC is involved in glomerular remodeling and repair, a process commonly associated with mesangioproliferative glomerulonephritis and diabetic nephropathy. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12577314     DOI: 10.1002/jcb.10424

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  19 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Developmental expression of Smoc1 and Smoc2 suggests potential roles in fetal gonad and reproductive tract differentiation.

Authors:  Dorothy E Pazin; Kenneth H Albrecht
Journal:  Dev Dyn       Date:  2009-11       Impact factor: 3.780

3.  Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.

Authors:  Isabella T Tai; Meiru Dai; David A Owen; Lan Bo Chen
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

4.  Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors.

Authors:  Kai Schledzewski; Cyrill Géraud; Bernd Arnold; Shijun Wang; Hermann-Josef Gröne; Tibor Kempf; Kai C Wollert; Beate K Straub; Peter Schirmacher; Alexandra Demory; Hiltrud Schönhaber; Alexei Gratchev; Lisa Dietz; Hermann-Josef Thierse; Julia Kzhyshkowska; Sergij Goerdt
Journal:  J Clin Invest       Date:  2011-02       Impact factor: 14.808

5.  Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.

Authors:  Matthew J Socha; Marlina Manhiani; Neveen Said; John D Imig; Kouros Motamed
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  The SPARC-related factor SMOC-2 promotes growth factor-induced cyclin D1 expression and DNA synthesis via integrin-linked kinase.

Authors:  Peijun Liu; Jining Lu; Wellington V Cardoso; Cyrus Vaziri
Journal:  Mol Biol Cell       Date:  2007-11-07       Impact factor: 4.138

Review 7.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

8.  SPARC accelerates disease progression in experimental crescentic glomerulonephritis.

Authors:  Amy N Sussman; Tong Sun; Ronald M Krofft; Raghu V Durvasula
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.

Authors:  G Chen; X Tian; Z Liu; S Zhou; B Schmidt; D Henne-Bruns; M Bachem; M Kornmann
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.